{"id":2922,"date":"2017-10-09T02:56:20","date_gmt":"2017-10-09T07:56:20","guid":{"rendered":"https:\/\/issels.com\/blog\/?p=2922"},"modified":"2017-09-23T18:59:16","modified_gmt":"2017-09-23T23:59:16","slug":"the-first-in-10-years-fda-approves-new-liver-cancer-drug","status":"publish","type":"post","link":"https:\/\/issels.com\/blog\/2017\/10\/09\/the-first-in-10-years-fda-approves-new-liver-cancer-drug\/","title":{"rendered":"The First in 10 Years – FDA Approves New Liver Cancer Drug"},"content":{"rendered":"
\"FDA
FDA Approves New Drug! Could This Make Groundbreaking Progress?<\/figcaption><\/figure>\n

In November 2007, the Food and Drug Administration gave its first-ever approval for a drug designed as liver cancer treatment<\/a>. Nearly 10 years later, the FDA has given its approval to a second drug for liver cancer<\/a> that also has applications for some forms of gastrointestinal cancer.<\/p>\n

The Search for Effective Liver Cancer Treatment<\/strong><\/p>\n

Sorafenib, brand name Nexavar\u00ae, was the original drug approved for treatment of hepatocellular carcinoma (HCC)<\/a>, which is the most common form of liver cancer. The drug acts as a kinase inhibitor to block enzymes responsible for cell division and reproduction.<\/p>\n

According to Dr. Tim Greten of NCI’s Center for Cancer Research, since 2007 there have been a number of phase III trials for possible liver cancer treatments. Until now, none of them have been successful.<\/p>\n

A 10-Year Breakthrough<\/strong><\/p>\n

Regorafenib, brand name Stivarga\u00ae, is also a kinase inhibitor. During a phase III trial, 573 patients whose HCC had not responded to sorafenib were assigned to receive either regorafenib or a placebo.<\/p>\n

The patients who received regorafenib experienced an overall three-month increase in survival over the placebo group. Percentage of patients whose tumors had at least partial shrinkage was 11 percent and four percent respectively.<\/p>\n

Researchers are also studying the use of other immunotherapy agents against liver cancer. The current focus is on checkpoint inhibitors<\/a> such as tremelimumab and nivolumab.<\/p>\n

Issels\u00ae: The Leader in Immunotherapy for All Forms of Cancer<\/strong><\/p>\n

Our individually created immunotherapy programs have helped patients with stage IV HCC<\/a> and other forms of tumors in all stages. Visit our website<\/a> to find out why Issels\u00ae is ahead of the curve with integrative, non-toxic cancer treatment.<\/p>\n","protected":false},"excerpt":{"rendered":"

In November 2007, the Food and Drug Administration gave its first-ever approval for a drug designed as liver cancer treatment. Nearly 10 years later, the FDA has given its approval to a second drug for liver cancer that also has applications for some forms of gastrointestinal cancer. The Search for Effective Liver Cancer Treatment Sorafenib, … Continue reading The First in 10 Years – FDA Approves New Liver Cancer Drug<\/span> →<\/span><\/a><\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[203,216,538,2],"tags":[627,282,212],"class_list":["post-2922","post","type-post","status-publish","format-standard","hentry","category-cancer-research","category-immunotherapy","category-immunotherapy-for-cancer","category-news","tag-breakthrough-news","tag-cancer-news","tag-cancer-research"],"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/issels.com\/blog\/wp-json\/wp\/v2\/posts\/2922","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/issels.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/issels.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/issels.com\/blog\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/issels.com\/blog\/wp-json\/wp\/v2\/comments?post=2922"}],"version-history":[{"count":2,"href":"https:\/\/issels.com\/blog\/wp-json\/wp\/v2\/posts\/2922\/revisions"}],"predecessor-version":[{"id":2939,"href":"https:\/\/issels.com\/blog\/wp-json\/wp\/v2\/posts\/2922\/revisions\/2939"}],"wp:attachment":[{"href":"https:\/\/issels.com\/blog\/wp-json\/wp\/v2\/media?parent=2922"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/issels.com\/blog\/wp-json\/wp\/v2\/categories?post=2922"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/issels.com\/blog\/wp-json\/wp\/v2\/tags?post=2922"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}